Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades

Marsigliante, Santo; Muscella, Antonella; Ciardo, V; Barker, Stewart; Leo, Giuseppe; Baker, V.A; Mottaghi, Ali; Vinson, Gavin P.; Storelli, Carlo

doi:10.1016/0304-3835(93)90062-e

Cited by 21 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This value is in agreement with the previous findings (Dutta et al, 2008), where HER-2/ neu positivity was seen in 57.2% of BC cases. But, in follow-up studies, HER-2/neu positivity was seen only in 29% of Invasive BC cases from Bangalore city, South India (Marsiglinate et al, 1993). Vaidyanathan et al from the same region reported it to be 43.2% positivity in BC cases (Vaidyanathan et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

HER-2/neu Status: A Neglected Marker of Prognostication and Management of Breast Cancer Patients in India

Zubeda¹,

Kaipa²,

Shaik³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Categorizing breast tumors based on the ER, PR and HER/Neu 2 receptor status is necessary in order to predict outcome and assist in management of breast cancer. Herfe we assessed this question in South Indian patients. Materials and Methods: A total of 619 formalin fixed paraffin embedded breast tumor tissues were collected from pathology archives after receipt of ethical clearance. With the help of primary and secondary conjugated antibodies, expression status of ER, PR and HER2/neu was determined. All the experimental data were assessed for correlations with histopathological features of tumors and clinical presentation of the subjects. Results: In the present study, the ages ranged from 20-87 years with a mean of 50.0±12.q years, and majority of the tumors (84%) were of infiltrating duct cell carcinoma type. Assessment of ER, PR and Her-2/neu expression showed that 46% were triple negative. Interestingly, an inverse relation between ER, PR and HER-2/neu was apparent in 41.2% (p<0.0001) of the tumors, of which 24.5% (p<0.0001) were ER and PR co-negative but HER-2 positive. Conclusions: ER and PR positive tumors are less common (i.e<30%) compared to HER-2/neu positive tumors (i.e>50%) in Indian breast cancer patients, underlining the need for effective diagnostic screening and specific therapeutic managements in order to improve the survival rate of patients in low resource countries such as India.

show abstract

Section: Discussionmentioning

confidence: 99%

HER-2/neu Status: A Neglected Marker of Prognostication and Management of Breast Cancer Patients in India

Zubeda¹,

Kaipa²,

Shaik³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Experimental and clinical studies have found that within individual tumors, the strength of HER2+ and ER+ expression is generally inversely related [17][18][19][20][21][22]. Accordingly, one would anticipate that HER2+ER+ tumors would be relatively uncommon in the general population [23].…”

Section: Frequency Distribution For Her2 (±) And/or Er (±) Expressionmentioning

confidence: 99%

Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program

Anderson

Luo

Chatterjee

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

Background-In 2001, the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program established Residual Tissue Repositories (RTR) in the Hawaii, Iowa, and Los Angeles Tumor Registries to collect discarded tissue blocks from pathologic laboratories within their catchment areas. To validate the utility of the RTR for supplementing SEER's central database, we assessed human epidermal growth factor receptor-2 (HER2) and estrogen receptor expression (ER) in a demonstration project.

show abstract

“…As with ER, there is an inverse relationship between PR expression and HER2 expression (32,33). We therefore tested the hypothesis that both PR-negative and HER1-3-positive cancers exhibit de novo resistance to tamoxifen treatment, which in the light of the recent ATAC data would suggest these patients may derive greater benefit from early treatment with aromatase inhibitors.…”

mentioning

confidence: 99%

Can Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer?

Tovey¹,

Dunne

Witton³

et al. 2005

Clinical Cancer Research

136

126

View full text Add to dashboard Cite

Purpose: Resistance to tamoxifen is linked to overexpression of HER2, and aromatase inhibitors show particular benefit in progesterone receptor (PR)^negative patients.We previously reported reduced survival in patients overexpressing HER1, HER2, and HER3. We now show that both HER1-3 and PR status predicts for early relapse in estrogen receptor (ER)^positive tamoxifentreated breast cancer patients. Experimental Design: Tissue microarray technology was used to analyze 402 ER-positive tamoxifen-treated patients. Immunohistochemistry using epidermal growth factor receptor, HER2, HER3, HER4, and PR antibodies was done. Kaplan-Meier life table and Cox Regression analysis (log-rank testing of differences in breast cancer^related relapse on tamoxifen) was done. Results: HER1-3 (but not HER4) overexpression predicted for early relapse on tamoxifen (P = 0.0060). PR-negative cases were also significantly more likely to relapse while on tamoxifen (P = 0.017). HER1-3-positive and/or PR-negative patients combined as a ''high-risk'' group were significantly more likely to relapse on tamoxifen in univariate (P < 0.0001) and Cox's multivariate analysis (P = 0.0069). However, this applied to early relapse on tamoxifen only, as any disease relapse after 3 years of tamoxifen was unrelated to PR/HER status. Conclusions: We show that HER1-3 and PR status can identify time-dependent de novo tamoxifen resistance with risk declining markedly after 3 years of tamoxifen treatment. These results parallel data from the ATAC and Intergroup Exemastane Study trials which suggest that whereas PR-negative patients derive greater benefit from initial aromatase inhibitor treatment, PR status has no effect on response when given as delayed treatment to those disease free on tamoxifen after 3 years.

show abstract

Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades

Cited by 21 publications

References 26 publications

HER-2/neu Status: A Neglected Marker of Prognostication and Management of Breast Cancer Patients in India

HER-2/neu Status: A Neglected Marker of Prognostication and Management of Breast Cancer Patients in India

Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program

Can Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer?

Contact Info

Product

Resources

About